Abstract
Bullous pemphigoid is an autoimmune subepidermal blistering disorder that typically affects elderly adults but can also occur in childhood. We report on a 3-month-old boy who developed bullous pemphigoid 1 week after the second routine administration of a hexavalent vaccine. The disease was resistant to standard therapies (including oral and topical corticosteroids) but was relieved by intravenous immunoglobulin treatment. There was no recurrence of bullous pemphigoid after the next vaccination (3 mos after discontinuation of steroids).
© 2014 Wiley Periodicals, Inc.
MeSH terms
-
Betamethasone / therapeutic use
-
Diphtheria-Tetanus-Pertussis Vaccine / adverse effects*
-
Drug Resistance*
-
Drug Therapy, Combination
-
Exanthema
-
Glucocorticoids / therapeutic use*
-
Hepatitis B Vaccines / adverse effects*
-
Humans
-
Immunoglobulins, Intravenous / therapeutic use*
-
Infant
-
Male
-
Pemphigoid, Bullous / drug therapy
-
Pemphigoid, Bullous / etiology*
-
Poliovirus Vaccine, Inactivated / adverse effects*
-
Prednisolone / therapeutic use
Substances
-
Diphtheria-Tetanus-Pertussis Vaccine
-
Glucocorticoids
-
Hepatitis B Vaccines
-
Hexavac
-
Immunoglobulins, Intravenous
-
Poliovirus Vaccine, Inactivated
-
Betamethasone
-
Prednisolone